Adastra Holdings Ltd. (XTRX.CN)
| Previous Close | 0.5200 |
| Open | 0.0000 |
| Bid | 0.5000 x N/A |
| Ask | 0.5300 x N/A |
| Day's Range | 0.0000 - 0.0000 |
| 52 Week Range | |
| Volume | |
| Avg. Volume | 2,253 |
| Market Cap | 30.847M |
| Beta (5Y Monthly) | -0.73 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0590 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- ACCESSWIRE
Adastra Receives Controlled Substances Dealer's License
Adastra Holdings Ltd. (CSE:XTRX) (FRA:D2EP) ("Adastra" or the "Company"), a leading cannabis company focused on processing, adult-use and medical sales, organoleptic testing and analytical testing, is pleased to announce that the Company has received its Controlled Drug and Substances Dealer's License ("Dealer's License") on August 24, 2022.
- ACCESSWIRE
Adastra Signs Option to Terminate Legacy Supply Agreement to Streamline Operations and Maximize Revenue
Adastra Holdings Ltd. (CSE:XTRX)(FRA:D2EP) ("Adastra" or the "Company") is pleased to announce it has entered into an agreement effective August 30, 2022, with a third party (the "Agreement"), whereby Adastra has the right and option to terminate an exclusive amended license agreement dated December 4, 2020 (the "Phyto License Agreement") between the third party and 1204581 B.C.
- ACCESSWIRE
Adastra Holdings Reports Record Second Quarter Results; Momentum Accelerating in Second Half of the Year
Adastra Holdings Ltd. (CSE:XTRX)(FRA:D2EP) ("Adastra" or the "Company"), a leading cannabis company focused on processing, adult-use and medical sales, organoleptic testing and analytical testing, is pleased to report financial results for the three and six months ended June 30, 2022.
